Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03048292 · ClinicalTrials.gov registry record
New York City Mobile Interventional Stroke Team
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 191
- Enrollment target
NCT03048292: Completed study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT03048292 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 191 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03048292 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 191 participants
- Enrollment target
Study Summary
Endovascular treatment has recently become the recommended therapy for acute stroke after the publication of five randomized trials (MR CLEAN1, ESCAPE2, EXTEND IA3, SWIFT PRIME4, REVASCAT5) in 2015 that demonstrate its efficacy. Hospitals need to adapt to these updated stroke care guidelines, and many hospitals are not appropriately equipped for neurointerventional procedures. Decreased time to treatment is associated with favorable clinical outcomes, and best practices to optimize workflow between comprehensive stroke centers and secondary hospitals have become an important area of study. This prospective study is being conducted on acute stroke cases within the Mount Sinai Health System from 1 June 2016 up until 31 December 2018. The researchers would like to evaluate how variable methods of interventional service delivery for acute stroke affect clinical measures and outcomes. More specifically, the researchers are conducting this study in order to determine whether outcomes of neurointervention for large vessel occlusion in stroke, for patients presenting to and receiving treatment at a comprehensive stroke center, will be superior to that delivered by a mobilized intervention team at a central satellite hospital. In particular, the hypothesis is that factors affecting outcome include presentation to secondary hospital, delays with transfer including traffic conditions and time of day, and the acquisition of complex imaging within secondary hospitals.
Primary Outcome
Time between first hospital arrival and final recanalization
Interventions
- OTHER Acute Endovascular Stroke Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-07-16 |
What the finished NCT03048292 record still lists
NCT03048292 is an observational study that tracks outcomes without assigning an intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Acute Endovascular Stroke Treatment is the first listed.
NCT03048292 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03048292 about?
NCT03048292 is a clinical study titled "New York City Mobile Interventional Stroke Team". Endovascular treatment has recently become the recommended therapy for acute stroke after the publication of five randomized trials (MR CLEAN1, ESCAPE2, EXTEND IA3, SWIFT PRIME4, REVASCAT5) in 2015 that demonstrate its efficacy. Hospitals need to adapt to these updated stroke care guidelines, and ma...
What is the current status of trial NCT03048292?
This trial is currently completed. The enrollment target is 191 participants. The study started on 2016-06. Estimated completion is 2019-07-16.
What interventions are being tested in trial NCT03048292?
The interventions under investigation include: Acute Endovascular Stroke Treatment (OTHER).
Who is sponsoring clinical trial NCT03048292?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04621435 · 191 participants · Phase 1
Imaging of Solid Tumors Using FAP-2286
- NCT06810544 · 191 participants · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia